Kuwait Lung Adenocarcinoma Treatment Market Size & Outlook
Related Markets
Kuwait lung adenocarcinoma treatment market highlights
- The Kuwait lung adenocarcinoma treatment market generated a revenue of USD 15.4 million in 2023 and is expected to reach USD 29.2 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 9.5% from 2024 to 2030.
- In terms of segment, chemotherapy was the largest revenue generating treatment in 2023.
- Immunotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Lung adenocarcinoma treatment market data book summary
| Market revenue in 2023 | USD 15.4 million |
| Market revenue in 2030 | USD 29.2 million |
| Growth rate | 9.5% (CAGR from 2024 to 2030) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Other |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Eli Lilly and Co, Boehringer Ingelheim, Novartis AG ADR, Merck KGaA, AbbVie Inc, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.3% of the global lung adenocarcinoma treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia lung adenocarcinoma treatment market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 43.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Lung Adenocarcinoma Treatment Market Scope
Lung Adenocarcinoma Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Kuwait lung adenocarcinoma treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to lung adenocarcinoma treatment market will help companies and investors design strategic landscapes.
Chemotherapy was the largest segment with a revenue share of 39.61% in 2023. Horizon Databook has segmented the Kuwait lung adenocarcinoma treatment market based on chemotherapy, targeted therapy, immunotherapy, radiation therapy, other covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Kuwait lung adenocarcinoma treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Kuwait lung adenocarcinoma treatment market databook
-
Our clientele includes a mix of lung adenocarcinoma treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait lung adenocarcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait lung adenocarcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Kuwait lung adenocarcinoma treatment market size, by treatment, 2018-2030 (US$M)
Kuwait Lung Adenocarcinoma Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
